Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kontafarma China Holdings Ltd ( (HK:1312) ) has shared an update.
Kontafarma China Holdings Ltd has announced a restructuring of its board of directors, effective November 14, 2025. The company has appointed Wang Feifei as Chairman and President, with Guo Zixiu as Financial Controller, and Liu Jiankun as an Executive Director. The board also includes a Non-Executive Director and three Independent Non-Executive Directors. This restructuring is likely to impact the company’s governance and strategic direction, potentially influencing its market position and stakeholder confidence.
More about Kontafarma China Holdings Ltd
Average Trading Volume: 5,734,550
Technical Sentiment Signal: Sell
Current Market Cap: HK$150.6M
For an in-depth examination of 1312 stock, go to TipRanks’ Overview page.